News
APGE
135.07
0.00%
0.00
*News On Apogee Therapeutics Inc. (APGE) Now Under ABBV
Dow Jones · 09/03 21:09
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
NASDAQ · 09/03 15:02
State Street SPDR S&P Biotech ETF Experiences Big Inflow
NASDAQ · 09/03 14:55
AbbVie seals $11B acquisition of Apogee Therapeutics
Seeking Alpha · 09/03 13:24
Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting
TipRanks · 09/03 13:16
AbbVie completes acquisition of Apogee for $135.11 per share in cash
TipRanks · 09/03 12:41
*AbbVie Expects Acquisition to Negatively Impact Adj EPS by 14c in 2026 (Partial Year) >ABBV
Dow Jones · 09/03 12:38
*AbbVie Expects Acquisition to Negatively Impact Adj EPS by About 46c in 2027, With Accretion Beginning in 2032 >ABBV
Dow Jones · 09/03 12:38
*Apogee Hldrs Received $135.11 Per Shr in Cash, for Total Equity Value of About $10.9 B
Dow Jones · 09/03 12:37
*AbbVie Backs FY26 Adj EPS $13.87-Adj EPS $14.07 >ABBV
Dow Jones · 09/03 12:36
*AbbVie Backs 3Q Adj EPS $3.84-Adj EPS $3.88 >ABBV
Dow Jones · 09/03 12:36
Press Release: AbbVie Completes Acquisition of -2-
Dow Jones · 09/03 12:35
*AbbVie Completes Acquisition Of Apogee Therapeutics >ABBV APGE
Dow Jones · 09/03 12:35
Press Release: AbbVie Completes Acquisition of Apogee Therapeutics
Dow Jones · 09/03 12:35
Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE
NASDAQ · 09/02 07:34
Weekly Report: what happened at APGE last week (0824-0828)?
Weekly Report · 08/31 09:53
XBI, TWST, ORKA, APGE: Large Inflows Detected at ETF
NASDAQ · 08/25 14:54
Weekly Report: what happened at APGE last week (0817-0821)?
Weekly Report · 08/24 09:53
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026
Seeking Alpha · 08/17 12:26
Apogee Therapeutics downgraded to Neutral from Buy at BTIG
TipRanks · 08/17 10:16
More
Webull provides a variety of real-time APGE stock news. You can receive the latest news about Apogee Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.